Last reviewed · How we verify
Nanohydroxyapatite
Nanohydroxyapatite is a Small molecule drug developed by King Abdulaziz University. It is currently in Phase 1 development. Also known as: Bone graft.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Nanohydroxyapatite |
|---|---|
| Also known as | Bone graft |
| Sponsor | King Abdulaziz University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy Of Eggshell-Derived Nanohydroxyapatite Based Mineralized Plasmatic Matrix Versus Xenogeneic Based Mineralized Plasmatic Matrix in Posterior Mandibular Socket Preservation (NA)
- Evaluation of the Combined Effect of Bioactive Toothpastes, Desensitizing Agents and Er-YAG Laser on Dentin Hypersensitivity: an In-Vivo Study (NA)
- Effect of Nanohydroxyapatite Paste After Different Pretreatment Techniques on White Spot White Spot Lesions (NA)
- The Effect of Bone Marrow Stem Cells Harvested from the Iliac Crest Versus Mandibular Ramus in Alveolar Cleft Regeneration
- Assessment of L-PRF, Nanohydroxyapatite Combined With L-PRF Using Pulpotomy in Mature Mandibular First Molars (NA)
- Evaluation of Platelets Rich Fibrin and Nanohydroxyapatite in the Treatment of Intrabony Defects (EARLY_PHASE1)
- Study of People's Profile Living in France Who Could be Interested in the Use of a Nanohydroxyapatite Toothpaste
- Healing Assessment of Osseous Defects After Surgical Removal of Periapical Lesions (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nanohydroxyapatite CI brief — competitive landscape report
- Nanohydroxyapatite updates RSS · CI watch RSS
- King Abdulaziz University portfolio CI
Frequently asked questions about Nanohydroxyapatite
What is Nanohydroxyapatite?
Who makes Nanohydroxyapatite?
Is Nanohydroxyapatite also known as anything else?
What development phase is Nanohydroxyapatite in?
Related
- Manufacturer: King Abdulaziz University — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Bone graft
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing